Proteins and Peptides

18 Oct 2017 BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
18 Oct 2017 Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
16 Oct 2017 Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients
13 Oct 2017 Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)
12 Oct 2017 Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
12 Oct 2017 First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP0274
11 Oct 2017 Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in Chemotherapy-Induced Neutropenia
11 Oct 2017 US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim
10 Oct 2017 Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
10 Oct 2017 China Biologic Receives Approval for Commercial Manufacturing of Human Fibrinogen
10 Oct 2017 Evolus Announces Presentations of Phase II and Phase III Data of PrabotulinumtoxinA
10 Oct 2017 ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
03 Oct 2017 FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity In Adults
30 Sep 2017 Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
30 Sep 2017 CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia
30 Sep 2017 Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US
28 Sep 2017 Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
28 Sep 2017 AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)
28 Sep 2017 Protagenic’s Neuropeptide Shows Strong Efficacy in Treating Depression and Anxiety of Established Rodent Models
28 Sep 2017 Intarcia Provides Corporate Update
22 Sep 2017 Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint
21 Sep 2017 Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
21 Sep 2017 Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
19 Sep 2017 TSI Completes Phase 1 Clinical Trial of Novel Clot-dissolving Therapy, TS01
18 Sep 2017 U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top